| Bioactivity | CMLD010509 (SDS-1-021) is a highly specific inhibitor of the oncogenic translation program supporting multiple myeloma (MM)-including key oncoproteins such as MYC, MDM2, CCND1, MAF, and MCL-1. CMLD010509 (SDS-1-021) shows an IC50 below 10 nM for most MM cell lines and induces apoptosis. CMLD010509 (SDS-1-021) is a potent and selective translation inhibitor through an eIF4E phosphorylation-independent mechanism[1]. |
| Name | CMLD010509 |
| CAS | 256497-58-2 |
| Formula | C27H26BrNO7 |
| Molar Mass | 556.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Manier S, et al. Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. Sci Transl Med. 2017 May 10;9(389). pii: eaal2668. |
CMLD010509
CAS: 256497-58-2 F: C27H26BrNO7 W: 556.40
CMLD010509 (SDS-1-021) is a highly specific inhibitor of the oncogenic translation program supporting multiple myeloma (
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.